Emerging Trend of Acinetobacter Nosocomial Infection in Northeast of Iran

  • Samaneh Saed Antimicrobial Resistance Research Center, Buali Research Institute, Department of Microbiology and Virology, Medical School, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • Malektaj Yazdanpanah Ghaem University Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • Mitra Lal-Dehghani Ghaem University Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • AmirReza Khalighi Ghaem University Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • Mahbubeh Honarmand Ghaem University Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • Parviz Afrough Department of Bacteriology, Medical University of Alborz, Alborz, IR Iran.
  • Kiarash Ghazvini Antimicrobial Resistance Research Center, Buali Research Institute, Department of Microbiology and Virology, Medical School, Mashhad University of Medical Sciences, Mashhad, IR Iran.
Keywords:
Acinetobacter, Cross Infection, Iran

Abstract

Background: Acinetobacter spp. emerged as an opportunistic pathogen for hospital-acquired infections. Recently, increasing antibiotic resistance among Acinetobacter spp. has worsened the problem. The aim of this study was to investigate  the  emerging  trend  of  infection  due  to Acinetobacter  in Ghaem University Hospital, Mashhad during 2006-2012.Methods: The demographic data and information about redisposing factors was collected. Appropriate bacteriological samples were collected and Acinetobacter spp. was isolated. Antibiotics susceptibility pattern of these isolates against different antimicrobials agents was determined.Results: Results confirmed that Acinetobacter spp. cause 20.9% of nosocomial infection during this period. The trend of Acinetobacter nosocomial infection was increasing and patients with risk factors such as COPD, bronchectasia, diabetes   mellitus   were   more   prone   to   infection.  There   was   significant association   between   these   infections   and   invasive   procedures   such   as catheterization, mechanical ventilation and broad-spectrum antibiotics usage.Conclusion:  Understanding  trends  in  causative  organisms  of  nosocomial infection can help us to better define our infection control policy.

References

Sengupta S, Kumar P, Ciraj A.M, et al.Acinetobacter baumannii - An emerging nosocomial pathogen in the burns unit Manipal, India. Burns 2001; 27: 140-4.

Jang T.-N, Lee S.-H, Huang C.-H, et al.Risk factors and impact of nosocomial Acinetobacter baumannii blood stream infections in the adult intensive care unit: a case-control study. J Hosp Infec 2009; 73: 143-50.

Paul M, Weinberger M, Siegman-Igra Y, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infec 2005; 60: 256-60.

Fournier PE, Richet H. The Epidemiology and Control of Acinetobacter baumannii in Health Care Facilities. Clin Infect Dis 2006;42: 692-9.

Gerner-Smidt P. Endemic occurrence of Acinetobacter calcoaceticus biovar anitratus in an intensive care unit. J Hosp Infec 1987; 10: 265-72.

Irfan S, Turton JF, Mehraj J, et al.Molecular and epidemiological characterisation of clinical isolates of carbapenem-resistant Acinetobacter baumannii from public and private sector intensive care units in Karachi, Pakistan. J Hosp Infec 2011; 78: 143-8.

Forbes Betty A, Sahm Daniel F, Weissfeld Alice S, 2007. BAILEY & SCOTT'S Diagnostic Microbiology, international edition, 12th ed. Mosby, an affiliate of Elsevier Inc.

Bergogne-Be´Re´Zin E, Towner KJ.Acinetobacter spp. as Nosocomial Pathogens: Microbiological, Clinical, and Epidemiological Features. Clin Microbiol Rev 1996; 9 (2):148-65.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLS document M100-S19. Wayne, Pa: CLSI; 2009.

Falagas ME, Kopterides P. Risk factors for the isolation of multi- drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infec 2006; 64: 7-15.

Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infec 2009; 73: 355-63.

Bergogne-Be´re´zin E. Resistance of Acinetobacter spp. to antimicrobials overview of clinical resistance patterns and therapeutic problems. In: Bergogne-Be´re´zin E, Joly-Guillou ML, Towner KJ, editors. Acinetobacter,microbiology,epidemiology, infections, management. Boca Raton: CRC Press;1996. p. 133-183.

Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42 (5): 692-9

Doi Y, Husain S, Potoski BA, et al.Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009;15: 980-2.

Van Looveren M, Goosens H, ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.

French GL, Casewell MW, Roncoroni AJ, et al. A hospital outbreak of antibiotic-resistant Acinetobacter anitratus : epidemiology and control. J Hosp Infec 1980; 1: 125-31.

Buxton AE, Anderson RL, Werdegar D, et al. Nosocomial respiratory tract infection and colonization with Acinetobacter calcoaceticus. Am J Med 1978; 65: 507-13.18. Forster DH, Daschner FD.Acinetobacter Species as Nosocomial Pathogens. Eur J Clin Microbiol Infect Dis 1998; 17: 73-7.

Published
2015-10-12
How to Cite
1.
Saed S, Yazdanpanah M, Lal-Dehghani M, Khalighi A, Honarmand M, Afrough P, Ghazvini K. Emerging Trend of Acinetobacter Nosocomial Infection in Northeast of Iran. J Med Bacteriol. 2(3-4):56-61.
Section
Original Articles